281 related articles for article (PubMed ID: 22039260)
21. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G
Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765
[TBL] [Abstract][Full Text] [Related]
22. Measurement of Residual Disease in Acute Myeloid Leukemia.
Vedula RS; Lindsley RC
Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
[TBL] [Abstract][Full Text] [Related]
23. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
25. Detection of minimal residual disease in acute myelogenous leukemia.
Raanani P; Ben-Bassat I
Acta Haematol; 2004; 112(1-2):40-54. PubMed ID: 15179004
[TBL] [Abstract][Full Text] [Related]
26. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia].
Wang YZ; Liu YR; Zhu HH; Wu HH; Cao H; Chan Y; Hao L; Jiang B; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):551-6. PubMed ID: 19549362
[TBL] [Abstract][Full Text] [Related]
29. Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
Paterno G; Del Principe MI; Venditti A
Curr Opin Hematol; 2020 Mar; 27(2):81-87. PubMed ID: 31895104
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
[TBL] [Abstract][Full Text] [Related]
31. Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?
Paietta E
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S2-6. PubMed ID: 26297274
[TBL] [Abstract][Full Text] [Related]
32. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
Chen X; Wood BL
Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
[TBL] [Abstract][Full Text] [Related]
33. Introducing minimal residual disease in acute myeloid leukemia.
Ofran Y; Rowe JM
Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
[TBL] [Abstract][Full Text] [Related]
34. [Clinical application of minimal residual disease detection in childhood acute leukemia].
Cheng YQ; Zhai XW
Zhongguo Dang Dai Er Ke Za Zhi; 2018 May; 20(5):416-420. PubMed ID: 29764581
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
36. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
37. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
38. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease in acute myeloid leukemia: coming of age.
Paietta E
Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
